Leitlinie zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem (COPD)

Vogelmeier, Claus; Buhl, Roland; Burghuber, O. C.; Criée, Carl-Peter; Ewig, Santiago; Godnič‐Cvar, Jasminka; Hartl, Sylvia; Herth, Felix J.F.; Kardos, Péter; Kenn, Klaus; Nowak, Dennis; Rabe, Klaus F.; Studnicka, Michael; Watz, Henrik; Welte, Tobias; Windisch, Wolfram; Worth, H.; e.V., Deutsche Gesellschaft für Rehabilitationswissenschaften

doi:10.1055/s-0043-125031

Cited by 128 publications

(92 citation statements)

References 466 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to the German Guideline for COPD [17], 1,8-cineole is recommended in addition to other mucolytics for its expectorant activity in dyscrinemic mucus. The guideline also recommends that substances with anti-inflammatory and antioxidant effects can be used to reduce exacerbations in patients with COPD and frequent exacerbations and points out that 1,8-cineole has been shown to significantly reduce exacerbations in patients with COPD and frequent exacerbations.…”

Section: Approved Efficacy Of 18-cineole In Randomized Placebo-contmentioning

confidence: 99%

New Perspectives for Mucolytic, Anti-inflammatory and Adjunctive Therapy with 1,8-Cineole in COPD and Asthma: Review on the New Therapeutic Approach

2020

View full text Add to dashboard Cite

The mucolytic monoterpene 1,8-cineole (eucalyptol), the major constituent of eucalyptus species, is well known for its anti-inflammatory, antioxidant, bronchodilatory, antiviral and antimicrobial effects. The main protective antiviral, anti-inflammatory and mucolytic mechanisms of 1,8-cineole are the induction of interferon regulatory factor 3 (IRF3), the control of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-jB) along with decreasing mucin genes (MUC2, MUC19). In normal human monocytes direct inhibition was shown of reactive oxygen species (ROS)-mediated mucus hypersecretion and of steroid resistence inducing superoxides (O 2 Á-) and pro-inflammatory hydrogen peroxides (H 2 O 2) with partial Digital Features To view digital features for this article go to

show abstract

Section: Approved Efficacy Of 18-cineole In Randomized Placebo-contmentioning

confidence: 99%

New Perspectives for Mucolytic, Anti-inflammatory and Adjunctive Therapy with 1,8-Cineole in COPD and Asthma: Review on the New Therapeutic Approach

2020

View full text Add to dashboard Cite

show abstract

“…According to the German COPD guidelines [29], there are a variety of treatments that COPD patients are recommended to integrate into their everyday life. Examples are physical exercises, physiotherapy, nutrition, and ergotherapy.…”

Section: Offering Rehabilitation Measuresmentioning

confidence: 99%

COPD: Rethinking Patient Management – How to Approach a Challenging Patient Group Successfully

et al. 2019

View full text Add to dashboard Cite

In comparison to other chronically ill people, patients suffering from chronic obstructive pulmonary disease (COPD) have many additional difficulties to face and conquer. Due to the contribution of avoidable causes of their illness (“smokers’ lung”), society holds people with COPD responsible for their disease, which in return often leads to stigmatization and social isolation. In addition, COPD patients commonly belong to a less privileged social class, own a low socioeconomic status, and lower education. Their physical symptoms are easily observable and – by employing moderate adherence – treatable. Nonetheless, the influence of COPD on a patient’s psyche often plays an overly prominent role during therapy. “There is only half a patient laying on the examination table,” a revelation that sums up the current state of COPD research and the result of the expert meeting “Luftschlösser” (“castles in the clouds”), which took place in spring 2018. Within the limits of the meeting, participants identified practically applicable approaches aiming to enhance the patient management of this challenging patient group. These considerations are supposed to support healthcare professionals in their daily work and aim to improve the therapy as well as the outcome for COPD patients.

show abstract

“…Die Diagnose der COPD wird anhand einer persistierenden Obstruktion der Atemwege, einer typischen Anamnese und bestimmten Risikofaktoren gestellt [30,31]. Eine Spirometrie mit Bronchospasmolysetest ist mindestens erforderlich, um die Diagnose einer COPD stellen zu können.…”

Section: Diagnose Der Copdunclassified

“…Für die COPD ist nachgewiesen, dass klinisch-anamnestische Angaben und objektiv identifizierte Komorbiditäten nur schwach miteinander korrelieren [40]. Somit werden bei allen Patienten mit COPD ein EKG und eine Echokardiografie zur Erkennung möglicher kardialer Komorbiditäten oder Folgeerkrankungen gefordert [30,31]. Andererseits sollte eine Spirometrie zumindest bei jenen Patienten mit Herzinsuffizienz erfolgen, bei denen Anhaltspunkte für eine pulmonale Begleiterkrankung vorliegen [41], wozu in jedem Fall auch (Ex-)Raucher gezählt werden müssen.…”

Section: Akute Situationunclassified

Herzinsuffizienz, COPD und Betablocker-Therapie

Borst

2019

Klinikarzt

View full text Add to dashboard Cite

ZUSAMMENFASSUNGHerzinsuffizienz und COPD sind häufig und begegnen uns vielfach gemeinsam. Jede der beiden Erkrankungen führt als Komorbidität der anderen zu einer erhöhten Morbidität und Mortalität, was eine erhöhte Aufmerksamkeit erfordert. Dies gilt in der stabilen Phase und besonders während akuter Dekompensation bzw. Exazerbation. Eine exakte Diagnostik ist notwendig. Sie sollte bei Patienten mit COPD neben klinischen Parametern EKG, Echokardiografie und die Bestimmung eines natriuretischen Peptids umfassen, bei solchen mit Herzinsuffizienz zumindest eine Spirometrie. COPD und Herzinsuffizienz werden jeweils ohne Abstriche leitliniengerecht behandelt. Eine Therapie mit kardioselektiven Betablockern aus kardiologischer Indikation darf COPD-Patienten nicht verweigert werden, wie es vielfach der Fall ist. Vielmehr verbessert sie deren Prognose signifikant.

show abstract

Leitlinie zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem (COPD)

Cited by 128 publications

References 466 publications

New Perspectives for Mucolytic, Anti-inflammatory and Adjunctive Therapy with 1,8-Cineole in COPD and Asthma: Review on the New Therapeutic Approach

New Perspectives for Mucolytic, Anti-inflammatory and Adjunctive Therapy with 1,8-Cineole in COPD and Asthma: Review on the New Therapeutic Approach

COPD: Rethinking Patient Management – How to Approach a Challenging Patient Group Successfully

Herzinsuffizienz, COPD und Betablocker-Therapie

Contact Info

Product

Resources

About